Skip to main navigation Skip to search Skip to main content

CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Translated title of the contribution: CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
  • T.O. Bergmeijer
  • , P.W.A. Janssen
  • , J.C. Schipper
  • , K. Qaderdan
  • , M. Ishak
  • , R.S. Ruitenbeek
  • , F.W. Asselbergs
  • , A.W. van 't Hof
  • , W.J.M. Dewilde
  • , F. Spanó
  • , J.P.R. Herrman
  • , J.C. Kelder
  • , M.J. Postma
  • , A. de Boer
  • , V.H.M. Deneer
  • , J.M. ten Berg

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionCYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
Original languageUndefined/Unknown
Pages (from-to)16-22
Number of pages7
JournalAmerican Heart Journal
Volume168
Publication statusPublished - 2014

Cite this